Table: Sumitomo Pharma -6-MTH group results (IFRS)

Sumitomo Pharma

31/10/2022 06:30

Oct 31 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 6 months ended      6 months ended        Year to  
                Sep 30, 2022        Sep 30, 2021      Mar 31, 2023  
                   LATEST             YEAR-AGO           COMPANY    
                   RESULTS             RESULT           FORECAST    
  Sales            319.29              293.73            604.00     
                 (+8.7 pct)          (+12.3 pct)       (+7.9 pct)   
  Operating      loss 28.92             47.57          loss 30.00   
                                     (+0.1 pct)                     
  Pretax
  Net             loss 7.28             36.45          loss 15.00   
                                     (-2.3 pct)                     
  EPS Basic    loss 18.33 yen         91.75 yen      loss 37.76 yen 
  Ann Div                             28.00 yen         28.00 yen   
  -Q2 Div         14.00 yen           14.00 yen                     
  -Q4 Div                             14.00 yen         14.00 yen   
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T